GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) begin affecting appetite and blood sugar within days to weeks, but clinically meaningful outcomes develop more gradually
Direct delivery, no nutrient loss
They also act on the appetite centers in the brain, significantly reducing hunger and what is often called food noise. The dual-action drug tirzepatide works on both GLP-1 and GIP receptors, often leading to even greater efficacy
Since peptides mimic natural processes already happening in the body, most people tolerate them well
Additionally, someone may have Hashimotos but have a single thyrotoxic (producing too much thyroid hormone) nodule, resulting in hypo/hyperthyroid swings